Missing data shows Pfizer's antidepressant ineffective, says Germany's IQWiG
This article was originally published in Scrip
Executive Summary
Germany's health technology assessment institute, IQWiG, is raising a rumpus about publication bias after getting hold of unpublished clinical trial data for Pfizer's antidepressant, Edronax (reboxetine), showing the benefit-risk ratio for this drug has gone from positive to negative. The drug was licensed in some European countries in the 1990s, but the US declined its approval in 2001.